Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,246.93
-8.4700-0.67%
Post-market: 1,249.472.54+0.20%18:09 EDT
Volume:1.66M
Turnover:2.07B
Market Cap:1.18T
PE:41.86
High:1,262.14
Open:1,262.14
Low:1,230.95
Close:1,255.40
52wk High:1,292.65
52wk Low:694.23
Shares:945.38M
Float Shares:939.00M
Volume Ratio:0.60
T/O Rate:0.18%
Dividend:6.69
Dividend Rate:0.54%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:34.80
PE(LYR):54.33

Loading ...

Biopharma Pricing Power Seen as Key Swing Factor for Q2 Earnings, BofA Says

MT Newswires Live
·
Jul 11

BofA Securities Adjusts Eli Lilly Price Target to $1,334 From $1,251

MT Newswires Live
·
Jul 10

Biopharma Dealmaking on Way to Record Year, Says HSBC

Reuters
·
Jul 10

Eli Lilly price target raised to $1,334 from $1,251 at BofA

TIPRANKS
·
Jul 10

German Lawmakers Approve Healthcare Shake-up Aimed at Taming Costs

Reuters
·
Jul 10

South African Regulators Issue Recall of Ozempic Copies

Reuters
·
Jul 10

Eli Lilly's Eczema Treatment Ebglyss Receives Favorable Reimbursement Recommendation in Canada

Deep News
·
Jul 09

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 09

Canadian Health Agency's Positive Reimbursement Recommendation Boosts Eli Lilly's Eczema Drug Prospects and Stock

Deep News
·
Jul 09

Eli Lilly to Unveil New Alzheimer's Research Advances at AAIC 2026

Deep News
·
Jul 09

Eli Lilly to presents abstracts at 2026 AAIC on Kisunla trials

TIPRANKS
·
Jul 09

Lilly to Present New Long-term Extension Data on Alzheimer’s Drug Kisunla at AAIC 2026

Reuters
·
Jul 09

Eli Lilly: Q2 2026 Acquired Ipr&d Charges Estimated at $2.80b Pre-tax

THOMSON REUTERS
·
Jul 09

Lilly Expects Q2 Acquired IPR&D Charge of About $2.8 Billion Pretax, $3.02/sh Hit

Reuters
·
Jul 09

Eli Lilly's Positive Developments Drive Strong Performance for Goldman Sachs' Active Healthcare ETF

Deep News
·
Jul 09

Eli Lilly Could Deliver 'Beat-and-Raise' Quarter, Truist Says

MT Newswires Live
·
Jul 09

Sector Update: Healthcare

MT Newswires Live
·
Jul 09

Eli Lilly Expected to Beat Q2 Revenue Forecasts on Weight-Loss Drugs, RBC Says

MT Newswires Live
·
Jul 08

Update: Truist Securities Raises Price Target on Eli Lilly to $1,370 From $1,281, Keeps Buy Rating

MT Newswires Live
·
Jul 08

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

MT Newswires Live
·
Jul 08